About: Approaches to screening for hyperglycaemia in pregnant women during and after the COVID‐19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Approaches to screening for hyperglycaemia in pregnant women during and after the COVID‐19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Approaches to screening for hyperglycaemia in pregnant women during and after the COVID‐19 pandemic
Creator	Simmons, D Yamamoto, J Reynolds, R Scott, E Davie, Maria Myers, J Aiken, C Lindsay, R Mccance, D Meek, C Murphy, H
Source	Medline; PMC
abstract	AIM: To evaluate the diagnostic and prognostic performance of alternative diagnostic strategies to oral glucose tolerance tests, including random plasma glucose, fasting plasma glucose and HbA(1c), during the COVID‐19 pandemic. METHODS: Retrospective service data (Cambridge, UK; 17 736 consecutive singleton pregnancies, 2004–2008; 826 consecutive gestational diabetes pregnancies, 2014–2019) and 361 women with ≥1 gestational diabetes risk factor (OPHELIA prospective observational study, UK) were included. Pregnancy outcomes included gestational diabetes (National Institute of Health and Clinical Excellence or International Association of Diabetes and Pregnancy Study Groups criteria), diabetes in pregnancy (WHO criteria), Caesarean section, large‐for‐gestational age infant, neonatal hypoglycaemia and neonatal intensive care unit admission. Receiver‐operating characteristic curves and unadjusted logistic regression were used to compare random plasma glucose, fasting plasma glucose and HbA(1c) performance. RESULTS: Gestational diabetes diagnosis was significantly associated with random plasma glucose at 12 weeks [area under the receiver‐operating characteristic curve for both criteria 0.81 (95% CI 0.79–0.83)], fasting plasma glucose [National Institute of Health and Clinical Excellence: area under the receiver‐operating characteristic curve 0.75 (95% CI 0.65–0.85); International Association of Diabetes and Pregnancy Study Groups: area under the receiver‐operating characteristic curve 0.92 (95% CI 0.85–0.98)] and HbA(1c) at 28 weeks' gestation [National Institute of Health and Clinical Excellence: 0.83 (95% CI 0.75–0.90); International Association of Diabetes and Pregnancy Study Groups: 0.84 (95% CI 0.77–0.91)]. Each measure predicts some, but not all, pregnancy outcomes studied. At 12 weeks, ~5% of women would be identified using random plasma glucose ≥8.5 mmol/l (sensitivity 42%; specificity 96%) and at 28 weeks using HbA(1c) ≥39 mmol/mol (sensitivity 26%; specificity 96%) or fasting plasma glucose ≥5.2–5.4 mmol/l (sensitivity 18–41%; specificity 97–98%). CONCLUSIONS: Random plasma glucose at 12 weeks, and fasting plasma glucose or HbA(1c) at 28 weeks identify women with hyperglycaemia at risk of suboptimal pregnancy outcomes. These opportunistic laboratory tests perform adequately for risk stratification when oral glucose tolerance testing is not available.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1111/dme.14380
bibo:pmid	32750184
has license	no-cc
sha1sum (hex)	105aea6c37a52332a83daf6b7d18ea0c09fc6cb3
schema:url	https://doi.org/10.1111/dme.14380
resource representing a document's title	Approaches to screening for hyperglycaemia in pregnant women during and after the COVID‐19 pandemic
has PubMed Central identifier	PMC7436759
has PubMed identifier	32750184
schema:publication	Diabet Med
resource representing a document's body	covid:105aea6c37a52332a83daf6b7d18ea0c09fc6cb3#body_text
is schema:about of	named entity 'weeks' named entity 'New Zealand' named entity 'HbA1c' named entity 'strategies' named entity 'performed' named entity 'tests' named entity 'screening' named entity 'bloods' named entity 'hyperglycaemia' named entity 'plasma glucose' named entity 'public transport' named entity 'COVID-19 pandemic' named entity 'bloods' named entity 'hyperglycaemia' named entity 'GDM' named entity 'NICE' named entity 'risk factors' named entity 'mmol/l' named entity 'diabetes in pregnancy' named entity 'glucose challenge' named entity 'health outcomes' named entity 'Sanofi' named entity 'stillbirth' named entity 'OGTT' named entity 'risk factor' named entity 'metabolic' named entity 'GDM' named entity 'HbA1c' named entity 'FPG' named entity 'centiles' named entity 'stillbirth' named entity 'pregnancy' named entity 'CUH' named entity 'mother and child' named entity 'hyperglycaemia' named entity 'risk factors' named entity 'glucose' named entity 'fasting plasma glucose' named entity 'NICE' named entity 'GDM' named entity 'pregnant women' named entity 'iron deficiency' named entity 'FPG' named entity 'glucose' named entity 'mmol' named entity 'hyperglycaemia' named entity 'risk factors' named entity 'obesity' named entity 'pre-gestational diabetes' named entity 'FPG' named entity 'continuous glucose monitoring' named entity 'GDM' named entity 'polyhydramnios' named entity 'GDM' named entity 'pregnancy' named entity 'O'Sullivan' named entity 'plasma glucose' named entity 'diagnostic criteria' named entity 'glycaemic' named entity 'COVID-19 pandemic' named entity 'HbA1c' named entity 'glycaemic' named entity 'prognostic' named entity 'Australia' named entity 'ultrasound scans' named entity 'pregnancy' named entity 'odds ratios' named entity 'treatment of patients' named entity 'gestational age' named entity 'OPHELIA' named entity 'plasma glucose'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software